Hyperthermic intraperitoneal chemotherapy following cytoreductive surgery improves outcome in patients with primary appendiceal mucinous adenocarcinoma: A pooled analysis from three tertiary care centers

Oncologist

Volumn 20, Issue 8, 2015, Pages 907-914

  Shaib, Walid L ^a   Martin, Ludmila Katherine ^b   Choi, Minsing ^d   Chen, Zhengjia ^a   Krishna, Kavya ^b   Kim, Sungjin ^a   Brutcher, Edith ^a   Staley, Charles ^a   Maithel, Shishir K ^a   Philip, Philip ^d   Abdel Misih, Sherif ^c   Bekaii Saab, Tanios S ^b   El Rayes, Bassel F ^a  

^a EMORY UNIVERSITY   (United States)

^b Division of Hematology/Oncology   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

Appendiceal mucinous carcinoma; Hyperthermic intraperitoneal chemotherapy; Survival

Indexed keywords

FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; COLLOID CARCINOMA; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; ADENOCARCINOMA, MUCINOUS; APPENDICEAL NEOPLASMS; FEVER; INTRAPERITONEAL DRUG ADMINISTRATION; MIDDLE AGED; PROCEDURES; TERTIARY CARE CENTER;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; APPENDICEAL NEOPLASMS; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; FEVER; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MIDDLE AGED; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84940053610     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0294     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
2. Pai RK, Beck AH, Norton JA et al. Appendiceal mucinous neoplasms: Clinicopathologic study of 116 cases with analysis of factors predicting recurrence. Am J Surg Pathol 2009;33:1425–1439.
3. Young RH. Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms. Semin Diagn Pathol 2004;21:134–150.
4. Misdraji J, Yantiss RK, Graeme-Cook FM et al. Appendiceal mucinous neoplasms: A clinicopathologic analysis of 107cases. AmJ SurgPathol 2003;27: 1089–1103.
5. Smeenk RM, van Velthuysen ML, Verwaal VJ et al. Appendiceal neoplasms and pseudomyxoma peritonei:Apopulation based study. Eur J SurgOncol 2008;34:196–201.
6. Ronnett BM, Zahn CM, Kurman RJ et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. AmJSurg Pathol 1995;19:1390–1408.
7. Katz MH, Barone RM.The rationale of perioperative intraperitoneal chemotherapy in the treatmentof peritoneal surface malignancies. Surg Oncol Clin N Am 2003;12:673–688.
8. Ronnett BM, Yan H, Kurman RJ et al. Patients with pseudomyxoma peritonei associated with disseminated peritonealadenomucinosishaveasignificantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001;92:85–91.
9. Stewart JH IV, Shen P, Russell GB et al. Appendiceal neoplasms with peritoneal dissemination: Outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2006;13:624–634.
10. Gupta S, Parsa V, Adsay V et al. Clinicopathological analysis of primary epithelial appendiceal neoplasms. Med Oncol 2010;27:1073–1078.
11. Shapiro JF, Chase JL, Wolff RA et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: A single-institution experience. Cancer 2010;116:316–322.
12. Moran B, Baratti D, Yan TD et al. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol 2008;98:277–282.
13. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7: 69–76.
14. Chua TC, Moran BJ, Sugarbaker PH et al. Earlyand long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012;30:2449–2456.
15. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124–132.
16. Dayal S, Taflampas P, Riss S et al. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. Dis Colon Rectum 2013;56:1366–1372.
17. McBride K, McFadden D, Osler T. Improved survival of patients with pseudomyxoma peritonei receiving intraperitoneal chemotherapy with cytoreductive surgery: A systematic review and metaanalysis. J Surg Res 2013;183:246–252.
18. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359–374.
19. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Hoboken, NJ: Wiley- Interscience, 1980.
20. Cox DR. Regression models and life tables. J R Stat Soc, B 1972;34:187–220.
21. Overman MJ, Fournier K, Hu CY et al. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: The prognostic impact of histological grade. Ann Surg 2013;257:1072–1078.
22. Gough DB, Donohue JH, Schutt AJ et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 1994; 219:112–119.
23. Miner TJ, Shia J, Jaques DP et al. Long-term survival following treatment of pseudomyxoma peritonei: An analysis of surgical therapy. Ann Surg 2005;241:300–308.
24. Spratt JS, Adcock RA, Muskovin M et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980;40:256–260.
25. Sugarbaker PH. Surgical treatment of peritoneal carcinomatosis: 1988 Du Pont lecture. Can J Surg 1989;32:164–170.
26. Verwaal VJ, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737–3743.
27. Elias D, Delperro JR, Sideris L et al. Treatment of peritoneal carcinomatosis from colorectal cancer: Impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 2004;11:518–521.
28. Baratti D, Kusamura S, Nonaka D et al. Pseudomyxoma peritonei: Clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann SurgOncol 2008;15:526–534.
29. Bijelic L, Kumar AS, Stuart OA et al. Systemic chemotherapy prior to cytoreductive surgery and HIPEC for carcinomatosis from appendix cancer: Impact on perioperative outcomes and shortterm survival. Gastroenterol Res Pract 2012;2012: 163-284.
30. Faris JE, Ryan DP. Controversy and consensus on the management of patients with pseudomyxoma peritonei. Curr Treat Options Oncol 2013;14: 365–373.
31. Sugarbaker PH, Bijelic L, Chang D et al. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol 2010;102:576–581.